A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, multicenter, randomized, double-blind (within dose), placebo controlled,
parallel-group, dose-range finding study to evaluate the efficacy and safety of TF0023 spray
versus placebo in functional improvement of patients with ischemic strokes under standard of
care.